List of Excipients in Branded Drug FABHALTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	AMMONIA	2030-12-05
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	FERRIC OXIDE RED	2030-12-05
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	FERRIC OXIDE YELLOW	2030-12-05
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	FERROSOFERRIC OXIDE	2030-12-05
Novartis Pharmaceuticals Corporation	FABHALTA	iptacopan	0078-1189	GELATIN	2030-12-05

Excipient Strategy and Commercial Opportunities for Fabhalta

Last updated: February 27, 2026

What are the key excipient considerations for Fabhalta?

Fabhalta, a pharmaceutical candidate under development, requires a carefully planned excipient strategy to optimize stability, bioavailability, and patient compliance. Critical excipient factors include the formulation type, route of administration, and targeted pharmacokinetic profile.

Primary Functions of Excipients in Fabhalta

• Stability: Protects the active pharmaceutical ingredient (API) from degradation.
• Bioavailability: Enhances dissolution and absorption.
• Patient compliance: Masks taste, improves ease of administration.
• Manufacturing: Facilitates processability, such as compression or liquid formulation.

Commonly Used Excipient Types

Excipient Type	Purpose in Fabhalta	Examples
Disintegrants	Promote tablet breakup for absorption	croscarmellose sodium, sodium starch glycolate
Binders	Provide tablet cohesion	microcrystalline cellulose, povidone
Lubricants	Reduce friction during manufacturing	magnesium stearate, stearic acid
Fillers/Diluents	Adjust tablet size and dose	lactose, microcrystalline cellulose
Solubilizers	Improve solubility of poorly soluble APIs	polysorbates, PEG 400
Stabilizers	Prevent API degradation	antioxidants like ascorbyl palmitate

Excipient Selection for Specific Formulation Routes

• Oral tablets: Disintegrants, binders, lubricants, diluents.
• Injectable formulations: Solubilizers, stabilizers, buffering agents.
• Topical formulations: Emollients, penetration enhancers, stabilizers.

What are the commercial opportunities associated with excipient choices?

Market Size and Trends

• The excipient market was valued at approximately USD 7.2 billion in 2020 (Grand View Research, 2021).
• Expected compound annual growth rate (CAGR) of 6.4% through 2028 (Grand View Research, 2021).
• Rising demand driven by increased biologics and complex formulations.

Regulatory Landscape

• Excipients are subject to pharmacopeial standards (e.g., USP, EP).
• Increasing focus on excipient safety and transparency.
• Emerging trends include the development of excipient baskets for personalized medicine.

Strategic Considerations

• Supply chain security: Multi-sourcing excipients to mitigate shortages.
• Regulatory compliance: Selecting established excipients with proven safety profiles.
• Innovation: Incorporating novel excipients for targeted delivery or improved stability.

Commercial Opportunity Analysis

• Custom-formulated excipients or specialized delivery systems can command premium pricing.
• Partnership with excipient suppliers for technology licensing.
• Development of proprietary excipient blends tailored to Fabhalta’s unique characteristics.

Competitive Landscape

• Major excipient suppliers include Roquette, Meggle-Aker, and Ashland.
• Trends favor developing excipients with enhanced functionalities, such as multifunctional carriers.

What strategies should be considered for excipient development and supply?

• Early-stage collaboration with suppliers to optimize formulations.
• Investing in excipient research to identify multifunctional or bio-based options.
• Regulatory engagement to streamline approval processes.
• Cost analysis for scale-up, balancing raw material costs with formulation benefits.

Wrap-up: Impact on Fabhalta's market potential

Optimizing excipient selection aligns with Fabhalta's development goals by enhancing drug stability, efficacy, and manufacturability. A robust excipient strategy supports regulatory approval, market access, and competitive differentiation.

---

Key Takeaways

• Excipient choices influence Fabhalta's stability, bioavailability, and patient friendliness.
• The excipient market is growing, with opportunities in innovative formulations.
• Regulatory requirements demand using excipients with established safety profiles.
• Partnerships and research can unlock premium formulations and reduce risks.
• Supply chain resilience and cost management are critical for large-scale manufacturing.

---

FAQs

1. How do excipients affect regulatory approval?
Excipients must meet pharmacopeial standards and demonstrate safety, impacting the approval timeline and process.

2. Can proprietary excipients provide competitive advantages?
Yes, they can improve formulation performance and enable patent protections.

3. What are trends in excipient development?
Development focuses on multifunctionality, bio-based sources, and compatibility with complex drug delivery systems.

4. How significant are supply chain risks for excipients?
Supply disruptions can delay production; multi-sourcing mitigates that risk.

5. What is the role of excipients in biologics?
Excipients stabilize proteins, prevent aggregation, and facilitate delivery.

---

References

[1] Grand View Research. (2021). Excipients Market Size, Share & Trends Analysis Report.
[2] U.S. Pharmacopeia. (2022). General Chapters and Monographs.